| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 79,317 | 95,713 | 77,344 | 87,721 |
| Marketable securities | 176,689 | 206,117 | 251,965 | 291,992 |
| Prepaid expenses and other current assets | 7,191 | 9,161 | 6,829 | 5,891 |
| Total current assets | 263,197 | 310,991 | 336,138 | 385,604 |
| Total property and equipment, at cost | NaN | 1,978 | NaN | NaN |
| Less accumulated depreciation and amortization | NaN | 1,521 | NaN | NaN |
| Property and equipment, net | 353 | 457 | 561 | 665 |
| Other assets | 3,048 | 3,136 | 5,475 | 4,394 |
| Operating lease right-of-use assets, net | 478 | 634 | 789 | 942 |
| Total assets | 267,076 | 315,218 | 342,963 | 391,605 |
| Accounts payable | 9,446 | 12,945 | 3,515 | 8,844 |
| Accrued expenses and other current liabilities | 23,287 | 25,996 | 15,828 | 10,454 |
| Current portion of operating lease liabilities | 634 | 843 | 832 | 821 |
| Total current liabilities | 33,367 | 39,784 | 20,175 | 20,119 |
| Operating lease liabilities | NaN | 0 | 213 | 425 |
| Income taxes payable | NaN | 0 | 6,795 | 6,645 |
| Total liabilities | NaN | 39,784 | 27,183 | 27,189 |
| Common stock, 0.001 par value 300,000,000 shares authorized 80,027,099 and 78,126,796 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 80 | 78 | 78 | 81 |
| Additional paid-in capital | 801,735 | 797,751 | 793,166 | 799,951 |
| Accumulated other comprehensive (loss) gain | -97 | 174 | 238 | 37 |
| Accumulated deficit | -568,009 | -522,569 | -477,702 | -435,653 |
| Total stockholders equity | 233,709 | 275,434 | 315,780 | 364,416 |
| Total liabilities and stockholders equity | 267,076 | 315,218 | 342,963 | 391,605 |
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)